Cihan Gani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7296878/publications.pdf

Version: 2024-02-01

		361045	454577
51	1,113	20	30
papers	citations	h-index	g-index
58	58	58	1259
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nature Reviews Clinical Oncology, 2021, 18, 805-816.	12.5	93
2	Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlentherapie Und Onkologie, 2012, 188, 148-153.	1.0	68
3	Partial breast irradiation with the 1.5ÂT MR-Linac: First patient treatment and analysis of electron return and stream effects. Radiotherapy and Oncology, 2020, 145, 30-35.	0.3	54
4	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiotherapy and Oncology, 2015, 116, 486-494.	0.3	48
5	Organ Preservation in Rectal Cancer: The Patients' Perspective. Frontiers in Oncology, 2019, 9, 318.	1.3	44
6	MR-Guided Radiotherapy for Liver Malignancies. Frontiers in Oncology, 2021, 11, 616027.	1.3	43
7	Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone. International Journal of Hyperthermia, 2012, 28, 707-714.	1.1	41
8	Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation. JMIR MHealth and UHealth, 2019, 7, e12345.	1.8	37
9	Quantitative magnetic resonance imaging on hybrid magnetic resonance linear accelerators: Perspective on technical and clinical validation. Physics and Imaging in Radiation Oncology, 2020, 16, 69-73.	1.2	36
10	Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic Review. Scientific Reports, 2019, 9, 2255.	1.6	34
11	Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncolmmunology, 2018, 7, e1496881.	2.1	33
12	Neutrophil-to-Lymphocyte Ratio in Rectal Cancer—Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?. International Journal of Molecular Sciences, 2019, 20, 2448.	1.8	33
13	Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5ÂT MR-Linac – Feasibility, workflow data and patient acceptance. Clinical and Translational Radiation Oncology, 2021, 26, 55-61.	0.9	30
14	Organ preservation in rectal cancer – Challenges and future strategies. Clinical and Translational Radiation Oncology, 2017, 3, 9-15.	0.9	29
15	Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. Strahlentherapie Und Onkologie, 2019, 195, 771-779.	1.0	29
16	Online MR guided radiotherapy for rectal cancer. New opportunities. Clinical and Translational Radiation Oncology, 2019, 18, 66-67.	0.9	27
17	MR-Guided Radiotherapy for Rectal Cancer: Current Perspective on Organ Preservation. Frontiers in Oncology, 2021, 11, 619852.	1.3	27
18	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Frontiers in Oncology, 2021, 11, 628155.	1.3	27

#	Article	IF	Citations
19	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer, 2022, 164, 18-29.	1.3	27
20	Comparison of treatment plans for aÂhigh-field MRI-linac and aÂconventional linac for esophageal cancer. Strahlentherapie Und Onkologie, 2019, 195, 327-334.	1.0	24
21	Quality of life and fatigue before and after radiotherapy in breast cancer patients. Strahlentherapie Und Onkologie, 2021, 197, 281-287.	1.0	23
22	Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer. International Journal of Hyperthermia, 2016, 32, 187-192.	1.1	22
23	MRI-Based Upper Abdominal Organs-at-Risk Atlas for Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 106, 743-753.	0.4	21
24	Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer. Cancers, 2021, 13, 1279.	1.7	21
25	Watchful Waiting after Radiochemotherapy in Rectal Cancer: When Is It Feasible?. Visceral Medicine, 2019, 35, 119-123.	0.5	19
26	Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. Radiotherapy and Oncology, 2018, 129, 575-581.	0.3	16
27	Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. Radiotherapy and Oncology, 2021, 159, 155-160.	0.3	16
28	Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. Cancers, 2019, 11, 562.	1.7	15
29	Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. Strahlentherapie Und Onkologie, 2013, 189, 482-485.	1.0	14
30	Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?!. Strahlentherapie Und Onkologie, 2012, 188, 782-787.	1.0	13
31	Limited disease of extra-pulmonary small cell carcinoma. Strahlentherapie Und Onkologie, 2012, 188, 269-273.	1.0	13
32	Cerebral metastases in extrapulmonary cell carcinoma. Strahlentherapie Und Onkologie, 2012, 188, 478-483.	1.0	13
33	1.5ÂT MR-linac planning study to compare two different strategies of rectal boost irradiation. Clinical and Translational Radiation Oncology, 2021, 26, 86-91.	0.9	13
34	A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling – Rationale and first in human. Radiotherapy and Oncology, 2021, 164, 37-42.	0.3	12
35	Online MR-guided radiotherapy – A new era in radiotherapy. Clinical and Translational Radiation Oncology, 2019, 18, 102-103.	0.9	11
36	Simulation CT-based radiomics for prediction of response after neoadjuvant chemo-radiotherapy in patients with locally advanced rectal cancer. Radiation Oncology, 2022, 17, 84.	1.2	11

#	Article	IF	CITATIONS
37	Analysis of the electron-stream effect in patients treated with partial breast irradiation using the 1.5ÂT MR-linear accelerator. Clinical and Translational Radiation Oncology, 2021, 27, 103-108.	0.9	10
38	Development and results of a patient-reported treatment experience questionnaire on a 1.5ÂT MR-Linac. Clinical and Translational Radiation Oncology, 2021, 30, 31-37.	0.9	9
39	Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunology, Immunotherapy, 2022, 71, 541-552.	2.0	8
40	Cervical Squamous Cell Lymph Node Metastases from an Unknown Primary Site: Survival and Patterns of Recurrence after Radiotherapy. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S12169.	0.6	7
41	Oncological outcome of carcinomas in the rectosigmoid junction compared to the upper rectum or sigmoid colon – A retrospective cohort study. European Journal of Surgical Oncology, 2019, 45, 2037-2044.	0.5	7
42	Innovative radiation oncology Together– Precise,ÂPersonalized,ÂHuman. Strahlentherapie Und Onkologie, 2021, 197, 1043-1048.	1.0	7
43	External validation of a rectal cancer outcome prediction model with a cohort of patients treated with preoperative radiochemotherapy and deep regional hyperthermia. International Journal of Hyperthermia, 2018, 34, 455-460.	1.1	6
44	Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2022, 167, 233-238.	0.3	6
45	Cost analysis of aÂwait-and-see strategy after radiochemotherapy in distal rectal cancer. Strahlentherapie Und Onkologie, 2018, 194, 985-990.	1.0	5
46	Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT. Clinical and Translational Radiation Oncology, 2020, 24, 83-87.	0.9	3
47	Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5â€⊤ MR-linac. Strahlentherapie Und Onkologie, 2022, 198, 622-629.	1.0	2
48	An Activity Tracker–Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials). JMIR Research Protocols, 2021, 10, e28524.	0.5	1
49	The patients view on genetics and functional imaging for precision medicine: a willingness-to-pay analysis. Personalized Medicine, 2022, , .	0.8	1
50	Acceptance of physical activity monitoring in cancer patients during radiotherapy, the GIROfit phase 2 pilot trial. Technical Innovations and Patient Support in Radiation Oncology, 2022, 22, 16-21.	0.6	1
51	Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?. Innovative Surgical Sciences, 2017, 3, 47-53.	0.4	0